RxDoctor Payments Data

Kevin Tsai, MD

Interventional Cardiology · Brooklyn, NYNPI 1366830689

Payments from drug & device makers

$13,803in general payments, 2019–2025

Across 363 payments — averaging $38.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$2K
  • AstraZeneca$2K
  • Boston Scientific$1K
  • Shockwave Medical, Inc$921
  • Abbott$887
  • Johnson & Johnson$838
  • plus $6K from 36 others

What the payments were for

  • Travel & lodging$1,0738%
  • Food & beverage$12,18388%
  • Education$5474%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,803 in reported general payments places this provider in the 55th percentile of 382 interventional cardiology providers in New York.

See all interventional cardiology providers in New York

Medicare billing

Part B allowed, 2024
$62,194
Medicare patients
228
Services billed
455

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan28$44,030
BrilintaTicagrelor30$28,515
EliquisApixaban17$28,325
JardianceEmpagliflozin16$20,333
FarxigaDapagliflozin Propanediol18$13,556
XareltoRivaroxaban13$12,061
Nifedipine ErNifedipine63$2,008
Metoprolol Succinate125$1,610
Atorvastatin Calcium117$1,457
Valsartan16$966
Hydralazine Hcl20$717
Isosorbide Mononitrate ErIsosorbide Mononitrate38$670
Losartan Potassium45$586
Rosuvastatin Calcium47$540
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide17$522

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$203$44,03028 claims
AstraZenecaBrilinta, Farxiga$1,657$42,07148 claims
PfizerEliquis$185$28,32517 claims
Boehringer IngelheimJardiance$570$20,33316 claims
Johnson & JohnsonXarelto$838$12,06113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 382 interventional cardiology providers in New York.

Other interventional cardiology in Brooklyn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →